| Basics |
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.
|
| IPO Date: |
May 22, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$202.58M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.98 | 3.86%
|
| Avg Daily Range (30 D): |
$0.35 | 4.18%
|
| Avg Daily Range (90 D): |
$0.61 | 4.28%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.41M |
| Avg Daily Volume (30 D): |
1.11M |
| Avg Daily Volume (90 D): |
.97M |
| Trade Size |
| Avg Trade Size (Sh.): |
65 |
| Avg Trade Size (Sh.) (30 D): |
79 |
| Avg Trade Size (Sh.) (90 D): |
69 |
| Institutional Trades |
| Total Inst.Trades: |
2,086 |
| Avg Inst. Trade: |
$2.05M |
| Avg Inst. Trade (30 D): |
$.93M |
| Avg Inst. Trade (90 D): |
$1.29M |
| Avg Inst. Trade Volume: |
.07M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.28M |
| Avg Closing Trade (30 D): |
$.92M |
| Avg Closing Trade (90 D): |
$1.24M |
| Avg Closing Volume: |
78.51K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-2.46
|
$-.49
|
$-.34
|
|
Diluted EPS
|
$-2.46
|
$-.49
|
$-.34
|
|
Revenue
|
$ 97.6M
|
$ 17.15M
|
$ 28.3M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -66.71M
|
$ -13.45M
|
$ -9.18M
|
|
Operating Income / Loss
|
$ -78.35M
|
$ -16.51M
|
$ -11.62M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -56.82M
|
$ -16.11M
|
$ -20.48M
|
|
PE Ratio
|
|
|
|
|
|
|
